×

Pegylated interleukin-10

  • US 10,471,126 B2
  • Filed: 02/06/2018
  • Issued: 11/12/2019
  • Est. Priority Date: 09/29/2000
  • Status: Expired due to Term
First Claim
Patent Images

1. A method of treating an inflammatory disease in a human subject comprising administering to said human subject a therapeutically effective amount of pharmaceutical composition comprising a monopegylated PEG-IL10 (mono-PEG-IL-10), the mono-PEG-IL-10 comprising one or more polyethylene glycol (PEG) molecules covalently attached via a linker to the alpha amino group of the N-terminal amino acid residue of a single subunit of IL-10, and a pharmaceutically acceptable carrier.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×